Willcocks Lisa
Cambridge University Hospital NHS Trust, Hills Road, Cambridge CB2 2QQ, UK.
Med. 2025 Jan 10;6(1):100564. doi: 10.1016/j.medj.2024.11.017.
The ALIGN trial demonstrates that atrasentan, an endothelin A (ETA) receptor antagonist, reduces proteinuria in patients with IgA nephropathy (IgAN), a key goal to slow progressive renal disease. These results are consistent with those from sparsentan, a combined ETA and angiotensin inhibitor, in IgAN, suggesting two-year data will show atrasentan improves renal outcomes.
ALIGN试验表明，内皮素A（ETA）受体拮抗剂阿曲生坦可降低IgA肾病（IgAN）患者的蛋白尿，这是延缓肾病进展的关键目标。这些结果与IgAN中ETA和血管紧张素联合抑制剂司帕生坦的结果一致，表明两年的数据将显示阿曲生坦可改善肾脏预后。
